The data demonstrated that both CAR-T cell groups with IL-2 injection exhibited anti-tumor effects compared to the NT+IL-2 group, with the anti-HER2-13 CAR-T group showing a statistically significantly greater reduction in tumor weight (p = 0.0322) (Fig. 6C,D). Here, ERBB2 is linked to neoplasm.